Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections

Viral infections are a common cause of morbidity worldwide. The emergence of Coronavirus Disease 2019 (COVID-19) has led to more attention to viral infections and finding novel therapeutics. The CRISPR-Cas9 system has been recently proposed as a potential therapeutic tool for the treatment of viral...

Descripción completa

Detalles Bibliográficos
Autores principales: Najafi, Sajad, Tan, Shing Cheng, Aghamiri, Shahin, Raee, Pourya, Ebrahimi, Zahra, Jahromi, Zahra Kargar, Rahmati, Yazdan, Sadri Nahand, Javid, Piroozmand, Ahmad, Jajarmi, Vahid, Mirzaei, Hamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Masson SAS. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872819/
https://www.ncbi.nlm.nih.gov/pubmed/35228065
http://dx.doi.org/10.1016/j.biopha.2022.112743
Descripción
Sumario:Viral infections are a common cause of morbidity worldwide. The emergence of Coronavirus Disease 2019 (COVID-19) has led to more attention to viral infections and finding novel therapeutics. The CRISPR-Cas9 system has been recently proposed as a potential therapeutic tool for the treatment of viral diseases. Here, we review the research progress in the use of CRISPR-Cas technology for treating viral infections, as well as the strategies for improving the delivery of this gene-editing tool in vivo. Key challenges that hinder the widespread clinical application of CRISPR-Cas9 technology are also discussed, and several possible directions for future research are proposed.

Ejemplares similares